VCYT · Nasdaq · ·
Next earnings: November 3, 2026
$46.08+1.9%Sep 29 close
Veracyte, Inc. is scheduled to report next on November 3, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $150.3M | $130.2M | +15.49% |
| Profit | $25.5M | -$980K | +2,701.02% |
| Profit per share | $0.31 | -$0.01 | +3,200.00% |
| Free Cash Flow | $43M | $32.3M | +32.95% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“Q2 was a milestone quarter for Veracyte as we launched two new products, Prosigna LDT and TrueMRD for MIBC, while also delivering strong double-digit revenue growth, profitability and cash generation,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Veracyte (Nasdaq: VCYT) is a global diagnostics company with a vision to transform cancer care for patients around the world. The company’s molecular tests assess the unique biology of each patient’s tumor to help clinicians answer essential questions about cancer care. Veracyte’s Diagnostics Platform combines broad genomic and clinical data, advanced bioinformatics and AI, and a powerful evidence-generation engine to support continued innovation and pipeline development . The company’s portfolio includes the Afirma® Genomic Sequencing Classifier test , Decipher® Bladder Genomic Classifier test , Decipher® Prostate Genomic Classifier test , Prosigna® Breast Risk of Recurrence test , and the TrueMRD™ Monitoring Test for MIBC .
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Veracyte, Inc.’s Item 2.02 8-K filed July 30, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Veracyte, Inc. has no earnings call transcript available.